BCL2 and B-cell chronic lymphocytic leukemia: Preclinical studies have indicated synergy between MEKi and fludarabine, PI3K inhibitors, and B‐cell lymphoma 2 (Bcl‐2) antagonists in CLL [10, 11, 12].